[Form 4] BIOCRYST PHARMACEUTICALS INC Insider Trading Activity

Rhea-AI Filing Summary

BioCryst Pharmaceuticals, Inc. (BCRX)9,600 shares of common stock at $7.14 per share in an open market sale, coded "S" for sale. After this transaction, the director beneficially owned 30,642 shares of BioCryst common stock in direct ownership form.

The shares were sold under a pre-arranged trading plan adopted on August 14, 2025 pursuant to Rule 10b5-1. This means the sale occurred automatically according to the plan’s terms rather than as a new discretionary trading decision by the director.

11/17/2025 - 04:07 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SANDERS MACHELLE

(Last) (First) (Middle)

4505 EMPEROR BLVD.

SUITE 200

(Street)

DURHAM NC 27703

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOCRYST PHARMACEUTICALS INC [ BCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/13/2025		S		9,600(1)	D	$7.14	30,642	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were sold pursuant to a plan adopted by the Reporting Person on August 14, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale occurred automatically and does not represent a discretionary transaction by the Reporting Person.

	/s/ Alane P. Barnes, by power of attorney	11/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did BioCryst (BCRX) disclose in this Form 4?

The filing reports that a BioCryst director sold 9,600 shares of common stock in a market sale coded as transaction type "S" on 11/13/2025.

At what price were the BioCryst (BCRX) shares sold and how many shares remain owned?

The shares were sold at a price of $7.14 per share. After the sale, the director beneficially owned 30,642 shares of BioCryst common stock.

Was the BioCryst (BCRX) insider sale a discretionary trade?

No. The 9,600-share sale occurred automatically under a pre-arranged Rule 10b5-1 trading plan and does not represent a discretionary transaction by the director.

When was the Rule 10b5-1 trading plan for the BioCryst (BCRX) director adopted?

The trading plan governing this sale was adopted on August 14, 2025 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934.

What is the reporting person’s relationship to BioCryst (BCRX)?

The reporting person in this Form 4 is a director of BioCryst Pharmaceuticals, Inc.

Is this Form 4 filing for a single reporting person or a group?

The Form 4 is indicated as being filed by one reporting person, not a joint or group filing.